RICHMOND, Va.--(BUSINESS WIRE)--Jan. 28, 2003--Insmed Incorporated (Nasdaq:INSM) will announce fourth quarter and full year financial results after market close on Monday, February 3.
The Company will host a conference call on Tuesday, February 4, at 8:00 a.m. Eastern Time (7:00 a.m. Central Time). Company management will conduct the call that will review the fourth quarter and provide an outlook for 2003.
To participate in the conference call dial 800-915-4836 (domestic) or 973-317-5319 (international). The call will be webcast live through Insmed's corporate website: www.insmed.com.
A telephonic replay of the call will be available for one week at 800-428-6051 (domestic) or 973-709-2089 (international), passcode: 283427. A web replay of the call will be available through the corporate website beginning at 10:00 a.m.
About Insmed Incorporated
Insmed Incorporated discovers and develops pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs. The Company's most advanced product candidate, SomatoKine®, is a novel delivery composition of IGF-I that regulates essential metabolic and anabolic (growth promoting) processes, including glucose uptake and tissue regeneration. Insmed is developing SomatoKine® for the treatment of Growth Hormone Insensitivity Syndrome (GHIS) and both type 1 and type 2 diabetes. The Company's second product candidate, rhIGFBP-3, is a recombinant protein that is being developed as an anti-cancer agent targeted towards the inhibition of solid tumor growth. Further information is available at the Company's corporate website: www.insmed.com.
CONTACT: Insmed Incorporated
Baxter Phillips, III, 804/565-3041 (Investor Relations)
bphillips@insmed.com
